ReviewRetrovirology2012
Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines.
Review in Retrovirology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women.PLoS pathogens · 2013Trial
- The RV144 Trial Might Still Yield Useful Information.Current HIV research · 2026Review
- Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.Journal of virology · 2022Review
- Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans.Science advances · 2021Review
- Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial.Journal of virology · 2019Article
- The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration.Frontiers in immunology · 2019Review
- Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.Viral immunology · 2018Review
- Surveillance for Intracellular Antibody by Cytosolic Fc Receptor TRIM21.Antibodies (Basel, Switzerland) · 2016Review
- How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.Expert review of vaccines · 2016Review
- Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein.AIDS research and human retroviruses · 2015Article
- Development of prophylactic vaccines against HIV-1.Retrovirology · 2013Review
- Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.Advances in biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Correlates of protection (CoPs) against infection by primate lentiviruses remain undefined. Modest protection against HIV-1 was observed in one human vaccine trial, whereas previous trials and vaccine-challenge experiments in non-human primates have yielded inconsistent but intriguing results. Although high levels of neutralizing antibodies are known to protect macaques from mucosal and intravenous viral challenges, antibody or other adaptive immune responses associated with protection might also be mere markers of innate immunity or susceptibility. Specific strategies for augmenting the design of both human trials and animal experiments could help to identify mechanistic correlates of protection and clarify the influences of confounding factors. Robust protection may, however, require the combined actions of immune responses and other host factors, thereby limiting what inferences can be drawn from statistical associations. Here, we discuss how to analyze immune protection against primate lentiviruses, and how host factors could influence both the elicitation and effectiveness of vaccine-induced responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.